Abbott
ABT
Market cap $201B

115.60 USD

+0.01

0.01%

At close Dec 6, 4:00 PM EST

After hours

115.41

-0.19

0.16%

1 day

0.01%

5 days

-2.65%

1 month

-1.03%

3 months

1.53%

6 months

10.87%

Year to date

5.23%

1 year

10.16%

5 years

35.24%

10 years

152.90%

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,794 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 185 | Existing positions closed: 166

9% more funds holding in top 10

Funds holding in top 10: 58 [Q2] → 63 (+5) [Q3]

6% more call options, than puts

Call options by funds: $1.1B | Put options by funds: $1.04B

4% more capital invested

Capital invested by funds: $141B [Q2] → $147B (+$5.63B) [Q3]

1% more funds holding

Funds holding: 2,808 [Q2] → 2,827 (+19) [Q3]

3.97% less ownership

Funds ownership: 77.9% [Q2] → 73.93% (-3.97%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 1,047 | Existing positions reduced: 1,174

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$117

1%

upside

Avg. target

$131

13%

upside

High target

$149

29%

upside

13 analyst ratings

9 positive

69%

4 neutral

31%

0 negative

0%

Barclays Matt Miksic 78% 1-year accuracy 21 / 27 met price target	29%upside $149	Overweight Maintained	5 Nov 2024
Bernstein Lee Hambright 67% 1-year accuracy 4 / 6 met price target	19%upside $138	Outperform Maintained	17 Oct 2024
UBS Danielle Antalffy 75% 1-year accuracy 6 / 8 met price target	26%upside $146	Buy Maintained	17 Oct 2024
Jefferies Matthew Taylor 25% 1-year accuracy 1 / 4 met price target	8%upside $125	Hold Maintained	17 Oct 2024
Mizuho Anthony Petrone 50% 1-year accuracy 19 / 38 met price target	12%upside $130	Neutral Maintained	17 Oct 2024

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about ABT published over the past 30 days

University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott

Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives Nebraska's win was announced at the Discover Big Ten Football Championship Game where the university received $1 million from global healthcare company Abbott to advance student and community health The competition, which will be back next fall, aims to help combat the greatest need for blood in a generation, while also helping create new lifelong blood donors ABBOTT PARK, Ill., and INDIANAPOLIS , Dec. 7, 2024 /PRNewswire/ -- This college football season, Abbott (NYSE: ABT) and the Big Ten put fandom and the hearts of Big Ten communities to the test with their inaugural blood donation competition, "The We Give Blood Drive.

University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott

Zacks Investment Research

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Abbott (ABT) closed at $115.59, marking a -0.33% move from the previous day.

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks Investment Research

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

Zacks Investment Research

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Zacks Investment Research

Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Abbott (ABT) stood at $118.77, denoting a -0.15% change from the preceding trading day.

Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors

Zacks Investment Research

Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues

Abbott has a unique opportunity to scale a capital-efficient licensing model that can help the emerging market population access life-changing medicines.

Growing EPD Business Supports ABT Stock Amid Macroeconomic Issues

Zacks Investment Research

The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems

Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems are included in this Analyst Blog.

The Zacks Analyst Blog Abbott, BlackRock, ConocoPhillips, NetSol and Optex Systems

Zacks Investment Research

ABT Stock Benefits From First Patient Procedures With TAVI System

Abbott announces its investigational TAVI balloon-expandable system???s first patient procedures.

ABT Stock Benefits From First Patient Procedures With TAVI System

The Best Large-Cap Stocks to Buy

Large-cap stocks are key additions to any well-rounded portfolio, but how do you find the best ones? We take a closer look here.

The Best Large-Cap Stocks to Buy

Zacks Investment Research

PAHC vs. ABT: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

PAHC vs. ABT: Which Stock Is the Better Value Option?

See News Rankings

Charts implemented using Lightweight Charts™